| Followers | 842 |
| Posts | 122795 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Tuesday, February 26, 2008 6:25:16 PM
[Updated based on guidance from BioCEO webcast.]
HIV
Mid 2008: Complete phase-1/2 IDX899 7-day monotherapy study using lower doses than 800mg. (Data from the 800mg cohort were reported on 2/6/08: #msg-26606685.) Report results at an unspecified conference.
3Q08: Start phase-2 IDX899 6-week combination study, IDX899+Truvada vs Sustiva+Truvada in first- or second-line patients.
2009: Partner IDX899 program following above phase-2 study.
HCV
April 2008: Report preclinical data on IDX184 ar EASL (#msg-27106080).
Mid 2008: File IND/CTA for IDX184.
End 2008: Report initial human data for IDX184.
1H09: File IND/CTA for HCV protease inhibitor.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
